Clinical Team Prepares Protocol for New Study of Ibogaine Treatment for Addiction in New Zealand
On October 17, 2011, the lead investigators for MAPS’ ibogaine research program held a conference call to discuss the next steps for our new observational study of ibogaine treatment for addiction in New Zealand. Thomas Kingsley Brown, Ph.D., who leads our U.S.-based study of independent ibogaine clinics in Mexico, and Geoff Noller, Ph.D., who will lead the new study, shared perspectives and lessons from ibogaine therapy research in order to guide the development of the new study protocol. The new study will take place at an independent ibogaine clinic in New Zealand, and will examine the safety and long-term effectiveness of ibogaine treatment for addiction severity and quality of life in 20 to 30 patients. The clinical team will submit the protocol and other documents to the Ethics Committee by the end of October.
Since this will be an observational study (as opposed to clinical) the protocol does not need to pass through an additional review process, meaning that we can begin enrolling subjects as soon as the study clears the Ethics Committee. Data from this study and our ongoing study of Mexican ibogaine treatment centers may be used to make a case for a possible future clinical study (see our original ibogaine Request for Proposals).